Does high-dose prophylactic acyclovir add benefit in allogeneic marrow transplant recipients receiving prophylactic or preemptive ganciclovir? [2] (multiple letters)

Journal of Infectious Diseases

Volumn 180, Issue 2, 1999, Pages 571-574

  De la Camara, R ^a   Fernandez Ranada, J M ^a   Boeckh, M ^a   Gooley, T ^a   Leisenring, W ^a   Myerson, D ^a   Corey, L ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GANCICLOVIR;

ALLOGENIC BONE MARROW TRANSPLANTATION; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG MEGADOSE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; PRIORITY JOURNAL; PROPHYLAXIS;

ACYCLOVIR; ANTIVIRAL AGENTS; BONE MARROW TRANSPLANTATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; GANCICLOVIR; HUMANS; PREMEDICATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033502697     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314892     Document Type: Letter

References (0)